SC
BDSX icon

Stempoint Capital’s Biodesix BDSX Stock Holding History

Stempoint Capital’s Portfolio BDSX Stock Details BDSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.58M Sell
70,000
-4
-0% -$59 0.27% 66
2026
Q1 		$1.02M Buy
+70,004
New +$868K 0.19% 67

Other funds holding BDSX

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TAM
Telemark Asset Management Boston, Massachusetts $1.38B AUM 71.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EIM
Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Stempoint Capital's BDSX Position: Q2 2026 in Review

Stempoint Capital reduced its Biodesix (BDSX) stake by 0.01% in Q2 2026, selling an estimated $59 and leaving 70,000 shares worth $1.58M. The position accounts for 0.27% of the portfolio, ranked #66.

Stempoint Capital first reported a position in BDSX in Q1 2026 and has held it in 2 quarters since. 45 funds tracked by Wall St. Rank hold BDSX as of Q2 2026.

  • Stempoint Capital held 70,000 shares of Biodesix worth $1.58M as of Q2 2026.
  • Stempoint Capital sold 4 Biodesix shares in Q2 2026, an estimated $59.
  • Biodesix made up 0.27% of Stempoint Capital's portfolio in Q2 2026, its #66 holding.
  • Stempoint Capital first reported a position in Biodesix in Q1 2026 and has held it in 2 quarters since.
  • 45 funds tracked by Wall St. Rank held Biodesix as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.